HRS-1738 Injection

Phase 1/2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

PET Imaging in Patients With Prostate Cancer

Conditions

PET Imaging in Patients With Prostate Cancer

Trial Timeline

Jul 1, 2025 → Aug 1, 2026

NCT ID

NCT07056439

About HRS-1738 Injection

HRS-1738 Injection is a phase 1/2 stage product being developed by Jiangsu Hengrui Medicine for PET Imaging in Patients With Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07056439. Target conditions include PET Imaging in Patients With Prostate Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07056439	Phase 1/2	Recruiting	Jul 1, 2025	Aug 1, 2026	PET Imaging in Patients With Prostate Cancer

Competing Products

20 competing products in PET Imaging in Patients With Prostate Cancer

See all competitors

Product	Company	Stage	Hype Score
HRS-9231 + Gadobutrol	Jiangsu Hengrui Medicine	Phase 2	52
Ranolazine + Placebo to match ranolazine	Gilead Sciences	Approved	84
Gadobutrol (Gadavist/Gadovist, BAY86-4875)	Bayer	Pre-clinical	20
Gadobutrol (Gadovist, BAY86-4875) + Gadopentetate Dimeglumine (Magnevist, BAY86-4882)	Bayer	Phase 3	74
Iopromide (Ultravist, BAY86-4877)	Bayer	Pre-clinical	20
Gadoquatrane (BAY1747846)	Bayer	Phase 3	74
BAY86-4367 + BAY86-4367	Bayer	Phase 1	30
GBCAs	Bayer	Pre-clinical	20
Gadobutrol (Gadovist, BAY86-4875)	Bayer	Phase 3	74
BAY1747846	Bayer	Phase 1	30
Gadoterate (Dotarem/Clariscan) + Gadobutrol (Gadavist/Gadovist, BAY86-4875)	Bayer	Approved	82
Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol	Bayer	Phase 3	74
Gadobutrol (Gadovist, BAY86-4875)	Bayer	Pre-clinical	20
F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102)	Bayer	Phase 1	30
Gadopentetate dimeglumine (Magnevist, BAY86-6661)	Bayer	Phase 3	74
Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol	Bayer	Phase 3	74
Ultravist (Iopromide, BAY86-4877)	Bayer	Pre-clinical	20
Gadopentetate dimeglumine (Magnevist, BAY86-4882)	Bayer	Pre-clinical	20
Gadoxetic Acid Disodium (Primovist, BAY86-4873)	Bayer	Pre-clinical	20
Gadobutrol (Gadavist, Gadovist, BAY86-4875)	Bayer	Phase 1	30

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved